<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319328</url>
  </required_header>
  <id_info>
    <org_study_id>H2019:031</org_study_id>
    <nct_id>NCT04319328</nct_id>
  </id_info>
  <brief_title>Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?</brief_title>
  <official_title>Pharmacokinetic Evaluation of Cefazolin, Ceftazidime, and Ciprofloxacin in Chronic Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Kidney Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to optimize the dosing of cefazolin, ceftazidime, and ciprofloxacin for&#xD;
      patients on high-flux hemodialysis. For each antibiotic 20 participants will be enrolled and&#xD;
      three blood samples will be collected from each participant. Antibiotic levels will be&#xD;
      measured in each blood sample. This data will be used to develop population-pharmacokinetic&#xD;
      models for each antibiotic. Finally, Monte Carlo simulations will be used to develop&#xD;
      evidence-based dosing recommendations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to optimize the dosing of three commonly used antibiotics, thereby&#xD;
      improving the treatment of serious, often life-threatening infections in patients on&#xD;
      intermittent high-flux hemodialysis (iHFHD).&#xD;
&#xD;
      The hypothesis is that current antibiotic dosing is suboptimal, thereby increasing the risk&#xD;
      of poor outcomes including treatment failure, adverse drug reactions and antibiotic&#xD;
      resistance.&#xD;
&#xD;
      A prospective, non-interventional pharmacokinetic (PK) study of cefazolin, ceftazidime, and&#xD;
      ciprofloxacin will be conducted in the St. Boniface Hospital outpatient hemodialysis unit.&#xD;
&#xD;
      The 1st objective of this study is to measure the free and total plasma concentrations of&#xD;
      cefazolin, ceftazidime, and ciprofloxacin in adult patients on iHFHD and receiving antibiotic&#xD;
      therapy for suspected or proven infection. For each antibiotic 20 participants will be&#xD;
      enrolled and three blood samples will be collected from each participant. Antibiotic&#xD;
      concentrations will be measured using an ultra high performance liquid chromatograph mass&#xD;
      spectrometer. Total antibiotic concentrations in plasma will be measured in all patient&#xD;
      samples. To describe protein binding, free levels will also be measured in the first two&#xD;
      samples collected from the first 10 patients for each antibiotic.&#xD;
&#xD;
      The 2nd objective of this study is to characterize the PK of cefazolin, ceftazidime, and&#xD;
      ciprofloxacin in patients on iHFHD using population-PK modelling. Covariates with potential&#xD;
      influence on PK such as gender, age, body weight, dialyzer type, blood and dialysate flow&#xD;
      rates, duration of dialysis and Kt/Vurea will be investigated, and incorporated as&#xD;
      appropriate. For each antibiotic, the best PK model will be selected using established&#xD;
      goodness-of-fit tests, and then independently validated.&#xD;
&#xD;
      The 3rd objective of this study is to translate findings to patient care using Monte Carlo&#xD;
      simulations to evaluate conventional antibiotic dosing and develop optimized evidence-based&#xD;
      dosing recommendations for cefazolin, ceftazidime, and ciprofloxacin in patients on iHFHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of distribution (Vd) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.</measure>
    <time_frame>48 to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug elimination (ke) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.</measure>
    <time_frame>48 to 72 hours</time_frame>
    <description>Drug elimination (ke) during and between dialysis sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug clearance (CL) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis.</measure>
    <time_frame>48 to 72 hours</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hemodialysis Complication</condition>
  <condition>Infectious Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftazidime</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <description>n = 20</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Non-interventional pharmacokinetic evaluation</description>
    <arm_group_label>Cefazolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>Non-interventional pharmacokinetic evaluation</description>
    <arm_group_label>Ceftazidime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Non-interventional pharmacokinetic evaluation</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients on chronic intermittent high-flux hemodialysis being treated for infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Proven or suspected infection&#xD;
&#xD;
          -  Receiving cefazolin, ceftazidime, or ciprofloxacin for treatment&#xD;
&#xD;
          -  Treatment course allows for collection of three 6 mL blood samples as per protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic liver disease, Child Pugh Class C or higher&#xD;
&#xD;
          -  Received study drug as part of a different treatment course in 1-week preceding start&#xD;
             of new treatment course&#xD;
&#xD;
          -  Acute kidney injury or recovering kidney function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheryl A Zelenitsky, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheryl A Zelenitsky, PharmD</last_name>
    <phone>204-474-8414</phone>
    <email>zelenits@umanitoba.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Boniface Hospital, Outpatient Hemodialysis Unit</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>College of Pharmacy, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0T5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl A Zelenitsky, PharmD</last_name>
      <phone>204-474-8414</phone>
      <email>zelenits@umanitoba.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Sheryl Zelenitsky</investigator_full_name>
    <investigator_title>Professor, College of Pharmacy, Rady Faculty of Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Antibiotic Dosing</keyword>
  <keyword>Cefazolin</keyword>
  <keyword>Ceftazidime</keyword>
  <keyword>Ciprofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

